Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph not_applicable
2
67%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Other(3)

Detailed Status

unknown3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 11 (33.3%)
N/A2 (66.7%)

Trials by Status

unknown3100%

Recent Activity

0 active trials
Showing 3 of 3
unknownnot_applicable

Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation

NCT03764228
unknownphase_1

Human Amniotic Epithelial Cells for Asherman's Syndrome

NCT03223454
unknownnot_applicable

Human Amniotic Epithelial Cells Treatment for Ovarian Insufficiency

NCT03207412

Clinical Trials (3)

Showing 3 of 3 trials
NCT03764228Not Applicable

Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation

Unknown
NCT03223454Phase 1

Human Amniotic Epithelial Cells for Asherman's Syndrome

Unknown
NCT03207412Not Applicable

Human Amniotic Epithelial Cells Treatment for Ovarian Insufficiency

Unknown

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3